XRAY Quote, Financials, Valuation and Earnings

Biolase has a net margin of 2.28% compared to Dentsply Sirona's net margin of -13.16%. Dentsply Sirona's return on equity of -35.57% beat Biolase's return on equity of -21668.17%.

Dentsply Sirona has a consensus price target of $18.14, signalling upside risk potential of 9.46%. On the other hand Biolase has an analysts' consensus of $1.2000 which suggests that it could grow by 19900%. Given that Biolase has higher upside potential than Dentsply Sirona, analysts believe Biolase is more attractive than Dentsply Sirona.

Dentsply Sirona has a beta of 0.924, which suggesting that the stock is 7.642% less volatile than S&P 500. In comparison Biolase has a beta of 0.016, suggesting its less volatile than the S&P 500 by 98.394%.

Dentsply Sirona has a quarterly dividend of $0.16 per share corresponding to a yield of 3.88%. Biolase offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dentsply Sirona pays -13.85% of its earnings as a dividend. Biolase pays out -- of its earnings as a dividend.

Dentsply Sirona quarterly revenues are $879M, which are larger than Biolase quarterly revenues of $10.9M. Dentsply Sirona's net income of $20M is higher than Biolase's net income of -$1.4M. Notably, Dentsply Sirona's price-to-earnings ratio is -- while Biolase's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dentsply Sirona is 0.89x versus 0.00x for Biolase. Usually stocks with elevated PS ratios are considered overvalued.

Milestone Scientific has a net margin of 2.28% compared to Dentsply Sirona's net margin of -89.35%. Dentsply Sirona's return on equity of -35.57% beat Milestone Scientific's return on equity of -79.98%.

Dentsply Sirona has a consensus price target of $18.14, signalling upside risk potential of 9.46%. On the other hand Milestone Scientific has an analysts' consensus of $2.13 which suggests that it could grow by 117.95%. Given that Milestone Scientific has higher upside potential than Dentsply Sirona, analysts believe Milestone Scientific is more attractive than Dentsply Sirona.

Dentsply Sirona has a beta of 0.924, which suggesting that the stock is 7.642% less volatile than S&P 500. In comparison Milestone Scientific has a beta of 0.934, suggesting its less volatile than the S&P 500 by 6.585%.

Dentsply Sirona has a quarterly dividend of $0.16 per share corresponding to a yield of 3.88%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dentsply Sirona pays -13.85% of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.

Dentsply Sirona quarterly revenues are $879M, which are larger than Milestone Scientific quarterly revenues of $2.2M. Dentsply Sirona's net income of $20M is higher than Milestone Scientific's net income of -$2M. Notably, Dentsply Sirona's price-to-earnings ratio is -- while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dentsply Sirona is 0.89x versus 9.07x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Envista Holdings has a net margin of 2.28% compared to Dentsply Sirona's net margin of 2.92%. Dentsply Sirona's return on equity of -35.57% beat Envista Holdings's return on equity of -34.78%.

Dentsply Sirona has a consensus price target of $18.14, signalling upside risk potential of 9.46%. On the other hand Envista Holdings has an analysts' consensus of $19.04 which suggests that it could grow by 2.76%. Given that Dentsply Sirona has higher upside potential than Envista Holdings, analysts believe Dentsply Sirona is more attractive than Envista Holdings.

Dentsply Sirona has a beta of 0.924, which suggesting that the stock is 7.642% less volatile than S&P 500. In comparison Envista Holdings has a beta of 0.975, suggesting its less volatile than the S&P 500 by 2.472%.

Dentsply Sirona has a quarterly dividend of $0.16 per share corresponding to a yield of 3.88%. Envista Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dentsply Sirona pays -13.85% of its earnings as a dividend. Envista Holdings pays out -- of its earnings as a dividend.

Dentsply Sirona quarterly revenues are $879M, which are larger than Envista Holdings quarterly revenues of $616.9M. Dentsply Sirona's net income of $20M is higher than Envista Holdings's net income of $18M. Notably, Dentsply Sirona's price-to-earnings ratio is -- while Envista Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dentsply Sirona is 0.89x versus 1.28x for Envista Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Solventum has a net margin of 2.28% compared to Dentsply Sirona's net margin of 6.62%. Dentsply Sirona's return on equity of -35.57% beat Solventum's return on equity of 11.75%.

Dentsply Sirona has a consensus price target of $18.14, signalling upside risk potential of 9.46%. On the other hand Solventum has an analysts' consensus of $81.27 which suggests that it could grow by 11.89%. Given that Solventum has higher upside potential than Dentsply Sirona, analysts believe Solventum is more attractive than Dentsply Sirona.

Dentsply Sirona has a beta of 0.924, which suggesting that the stock is 7.642% less volatile than S&P 500. In comparison Solventum has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Dentsply Sirona has a quarterly dividend of $0.16 per share corresponding to a yield of 3.88%. Solventum offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dentsply Sirona pays -13.85% of its earnings as a dividend. Solventum pays out -- of its earnings as a dividend.

Dentsply Sirona quarterly revenues are $879M, which are smaller than Solventum quarterly revenues of $2.1B. Dentsply Sirona's net income of $20M is lower than Solventum's net income of $137M. Notably, Dentsply Sirona's price-to-earnings ratio is -- while Solventum's PE ratio is 33.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dentsply Sirona is 0.89x versus 1.52x for Solventum. Usually stocks with elevated PS ratios are considered overvalued.